肉瘤新药他泽司他用法是怎样的？他泽司他国内上市了吗？

Epithelioid sarcoma, which commonly occurs in young adults aged 20-40 years, is a very rare and extremely aggressive soft tissue sarcoma. It was developed as a treatment for epithelioid sarcoma and was launched in the United States in 2020. The drug is the first and only approved EZH2 inhibitor. Today let’s learn in detail how to use the new sarcoma drug tazerestat? Is tazelast available in China?

Tazetostat, produced and developed by Epizyme, can reorganize the growth pathways of abnormal cells, promote cancer cell death and differentiation, and thereby shrink tumors. The recommended dose of the drug is 800 mg, which can be taken orally twice daily with or without food. During the medication period, patients are not allowed to increase or decrease the dose of the drug by themselves. Randomly increasing the dose of the drug will not improve the therapeutic effect, so do not use the medication blindly. And changes in dosage may have adverse effects.

Has the new sarcoma drug tazerestat, which has such an effective treatment effect, been launched in China? At present, tazerestat is not available in China, and patients cannot buy this drug in domestic hospital pharmacies, let alone use medical insurance for reimbursement. Patients in need can contact the medical companion travel service person to learn about the price and drug purchase process of the overseas version of tazerestat. It is a professional overseas medical service organization in China that can help patients obtain overseas drugs. It is cost-effective and affordable, and is suitable for patients to take drugs for a long time. Tazerestat represents a brand-new treatment method. Patients need to take symptomatic medication and take it on time and in the right amount to achieve the therapeutic effect of the drug.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: